Press release
Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Candidemia Clinical Trials
As per DelveInsight's assessment, globally, Candidemia pipeline constitutes 4+ key companies continuously working towards developing 4+ Candidemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Request for Sample Report here @ https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Candidemia Pipeline Report:
• Candidemia Companies across the globe are diligently working toward developing novel Candidemia treatment therapies with a considerable amount of success over the years.
• Candidemia companies working in the treatment market are Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals and others, are developing therapies for the Candidemia treatment
• Emerging Candidemia therapies such as Rezafungin, and others are expected to have a significant impact on the Candidemia market in the coming years.
• In January 2024, Cidara Therapeutics, Inc. announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (U.K.) approved REZZAYO (rezafungin acetate) for the management of invasive candidiasis in adults. REZZAYO is a new once-weekly echinocandin licensed in the United States to treat candidemia and invasive candidiasis in adults.
• In November 2023, Basilea Pharmaceutica Ltd stated that it had signed an asset purchase agreement with Amplyx Pharmaceuticals, Inc., a Pfizer Inc. company, to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. Additionally, Basilea has purchased the rights to a preclinical antifungal chemical.
• In July 2023, T2 Biosystems, Inc. declared that the US Food and Drug Administration (FDA) granted Breakthrough Device status for the Company's Candida auris (C. auris) direct-from-blood molecular diagnostic test.
Candidemia Overview
Candidemia is a serious bloodstream infection caused by Candida species, a type of yeast that normally resides on the skin and mucosal surfaces but can become invasive under certain conditions. It is the most common fungal bloodstream infection and is associated with high morbidity and mortality, particularly in immunocompromised individuals, hospitalized patients, and those with central venous catheters, prolonged antibiotic use, or underlying conditions like diabetes and cancer.
Symptoms of candidemia are often non-specific and may include fever, chills, hypotension, and signs of sepsis that do not improve with antibiotic treatment. If left untreated, the infection can spread to major organs, leading to complications such as endocarditis, meningitis, and kidney or liver dysfunction. Diagnosis is typically confirmed through blood cultures, but newer rapid diagnostic techniques, such as PCR and beta-D-glucan tests, can improve detection speed.
Treatment involves prompt administration of antifungal agents, with echinocandins (e.g., caspofungin, micafungin) as the first-line therapy. In some cases, fluconazole may be used as an alternative. Source control, such as removing infected catheters, is also crucial for successful treatment. Early diagnosis and appropriate antifungal therapy are essential to reducing mortality and improving patient outcomes.
Get a Free Sample PDF Report to know more about Candidemia Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Candidemia Route of Administration
Candidemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type
Candidemia Molecule Type
Candidemia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Candidemia Pipeline Therapeutics Assessment
• Candidemia Assessment by Product Type
• Candidemia By Stage and Product Type
• Candidemia Assessment by Route of Administration
• Candidemia By Stage and Route of Administration
• Candidemia Assessment by Molecule Type
• Candidemia by Stage and Molecule Type
DelveInsight's Candidemia Report covers around 4+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Candidemia product details are provided in the report. Download the Candidemia pipeline report to learn more about the emerging Candidemia therapies- https://www.delveinsight.com/report-store/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Candidemia Pipeline Analysis:
The Candidemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Candidemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Candidemia Treatment.
• Candidemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Candidemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Candidemia market.
Download Sample PDF Report to know more about Candidemia drugs and therapies- https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Candidemia Pipeline Drug Insight
• Coverage: Global
• Key Candidemia Companies: Cidara Therapeutics, Scynexis, Inc., Amplyx Pharmaceuticals and others.
• Key Candidemia Therapies: Rezafungin, and others.
• Candidemia Therapeutic Assessment: Candidemia current marketed and Candidemia emerging therapies
• Candidemia Market Dynamics: Candidemia market drivers and Candidemia market barriers
Request for Sample PDF Report for Candidemia Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/candidemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Candidemia Report Introduction
2. Candidemia Executive Summary
3. Candidemia Overview:
4. Candidemia- Analytical Perspective In-depth Commercial Assessment
5. Candidemia Pipeline Therapeutics
6. Candidemia Late Stage Products (Phase II/III)
7. Candidemia Mid Stage Products (Phase II)
8. Candidemia Early Stage Products (Phase I)
9. Candidemia Preclinical Stage Products
10. Candidemia Therapeutics Assessment
11. Candidemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Candidemia Companies
14. Candidemia Key Products
15. Candidemia Unmet Needs
16 . Candidemia Market Drivers and Barriers
17. Candidemia Future Perspectives and Conclusion
18. Candidemia Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market
• Acquired Immunodeficiency Syndrome Market: https://www.delveinsight.com/report-store/acquired-immunodeficiency-syndrome-aids-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Acute Pharyngitis Market: https://www.delveinsight.com/report-store/acute-pharyngitis-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Ada-scid Competitive Landscape: https://www.delveinsight.com/report-store/ada-scid-competitive-landscape-and-market-insight
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/licensing-services
Case study: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Candidemia Clinical Trials and Pipeline Analysis: EMA, PDMA, FDA Approvals, Medication, IND, NDA Approvals, Therapies, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 3865950 • Views: …
More Releases from DelveInsight Business Research
DelveInsight Enables Strategic Partner Identification for Oncology Biopharma Adv …
DelveInsight, a leading life science market research and strategic consulting firm, today announced the successful completion of a comprehensive Partner Identification and Assessment Program for a US-based mid-sized pharmaceutical company developing a novel clinical-stage oncology asset targeting Head and Neck Cancer. The engagement focused on identifying co-development and commercialization partners across the United States and European markets to accelerate late-stage clinical progress and market entry.
Discover how your oncology asset can…
DelveInsight Facilitates Global Out-Licensing Opportunity for Proprietary Neonat …
DelveInsight Business Research LLP, a leading healthcare strategic intelligence and consulting firm, today announced the successful completion of an out-licensing opportunity assessment for a Sweden-based biopharmaceutical innovator specializing in high-quality neonatal mesenchymal stem cells (MSCs). The engagement was focused on identifying global licensing partners with strong commercialization capabilities, with a strategic emphasis on Asia-Pacific expansion, where regenerative medicine markets are witnessing accelerated regulatory support and clinical adoption.
The client, a clinical-stage…
Yellow Fever Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluat …
(Las Vgas, Nevada, United States) As per DelveInsight's assessment, globally, Yellow Fever pipeline constitutes 3+ key companies continuously working towards developing 3+ Yellow Fever treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Yellow Fever Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers…
Influenza A Infections Market Positioned for Accelerated Development Through 203 …
The Influenza A Infections market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Influenza A Infections pipeline products will significantly revolutionize the Influenza A Infections market dynamics.
DelveInsight's "Influenza A Infections Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Influenza A Infections, historical and forecasted epidemiology as well as the Influenza A…
More Releases for Candidemia
Candidemia Market Growth, Trends, Consumer Demand and Key Opportunities
Introduction
Candidemia, a bloodstream infection caused by Candida species, is one of the most severe forms of invasive candidiasis. It represents a major healthcare challenge worldwide, particularly in immunocompromised individuals, intensive care unit (ICU) patients, and those with central venous catheters. The infection is associated with high morbidity, mortality, and healthcare costs, making it a critical focus of antifungal research and hospital infection control programs.
The market is shaped by rising prevalence…
Candidemia Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incid …
Candidemia companies working in the market are Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Scynexis, Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., Pfizer, and others.
(Albany, USA) DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Candidemia Market Size is Set for Rapid Growth as Innovative Treatments and Risi …
The Candidemia market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Cidara Therapeutics, Mycovia Pharmaceuticals, Scynexis, GSK, Basilea Pharmaceutica, Pfizer, Astellas Pharma Inc, Gilead Sciences, Scynexis, Inc., Merck Sharp & Dohme LLC
[Nevada, United States] - DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Candidemia, covering historical…
Candidemia Market Size Report 2032 | Market Drivers & Barriers, Clinical Trials …
(Albany, USA) DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Candidemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Candidemia market size from 2019 to…
Candidemia Market Forecast by 2032: Epidemiology Analysis, Emerging Therapies, R …
The Candidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Candidemia pipeline products will significantly revolutionize the Candidemia market dynamics.
DelveInsight's "Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Candidemia Market Report 2024-2034, Industry Size, Share, Trends and Future Grow …
Candidemia Market Size:
The candidemia market are expected to exhibit a CAGR of 3.16% during 2024-2034. The candidemia market report offers a comprehensive analysis of the market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the market share of various therapies, and the market's performance in the seven…
